NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · MID CAP
Cellectis S.a. CLLS
12 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$72.9M
▲ 75.8% vs FY2024
EPS · FY25
$-0.67
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-65.3%
Net margin · FY25
-92.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 72.9M
Revenue, FY2025 · full 12-year series below
Revenue
Net income
The company lost 93 cents on every revenue dollar this year.
Per share
USD -0.67
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-65.3%
Return on equity, FY2025
ROE
Operating margin-45.3%
Net margin-92.7%
Return on assets-19.1%
Each USD of equity lost 65 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+7.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+56.1%
+7.4%
+2.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.10B
Shares outstanding, FY2025
Change, 5 years+27.0%
Change, 10 years—
The share count grew 27% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 324.7M
total assets, end of FY2025
Total assetsUSD 324.7M
EquityUSD 75.9M
CashUSD 61.5M
Equity funds 23% of total assets.
History
12 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
0.1
0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.1
·
Operating income $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
EBITDA $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
·
Income tax $B
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
EPS, diluted $
−0.67
−0.41
−1.77
−2.33
−2.55
−1.91
−2.41
−1.93
−2.78
−1.91
−0.67
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−65.3
−34.1
−99.7
−62.6
−45.2
−27.1
−28.2
−23.3
−37.0
−24.1
−12.6
−1.8
Shares out B
0.10
0.10
0.07
0.05
0.05
0.04
0.04
0.04
0.04
0.04
0.04
0.03
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
35 of 35
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed